IAMA Therapeutics

Yamo Pharmaceuticals

This company develops pharmaceutical therapies to treat core social-interaction deficits for individuals with autism spectrum disorder.

Noema Pharma

This company develops clinical-stage therapeutic products for patients with central nervous system disorders and orphan neurological conditions.

Confluence Pharmaceuticals

This company develops therapeutic treatments for social and communication impairments in patients with Fragile X Syndrome and autism spectrum disorders.

Pano Therapeautics

This biotechnology company develops small molecule drugs targeting mitochondrial ion channels to treat neurodevelopmental disorders and complex diseases of aging.

Engrail Therapeutics

This company develops small-molecule therapies for patients with neurologic, neuropsychiatric and neurodevelopmental disorders such as anxiety, depression and rare diseases.

Neurosciences

This company develops precision sodium channel therapeutics to treat patients with neurological conditions such as genetic epilepsy and chronic neuropathic pain.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Mahzi Therapeutics

This biotechnology company develops gene and antisense oligonucleotide therapies for patients with rare genetic neurodevelopmental disorders.